PURPOSE: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy. MATERIALS AND METHODS: A retrospective analysis was performed involving 28 patients with histologic-proven ESSs treated at our institution between 1987 and 2006. RESULTS: The median follow-up was 54.7+/-63.1 months and the 5-year survival rate was 82.0%. Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively. Univariate analysis revealed that the histologic grades, based on mitotic count, were associated with longer survival (p=0.004). However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period. With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment. Adjuvant treatment after surgery was administered to 14/26 patients (53.8%). Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival. However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054). CONCLUSIONS: The preoperative differential diagnosis of ESSs from other benign gynecologic diseases is often difficult. We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis.
PURPOSE: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy. MATERIALS AND METHODS: A retrospective analysis was performed involving 28 patients with histologic-proven ESSs treated at our institution between 1987 and 2006. RESULTS: The median follow-up was 54.7+/-63.1 months and the 5-year survival rate was 82.0%. Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively. Univariate analysis revealed that the histologic grades, based on mitotic count, were associated with longer survival (p=0.004). However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period. With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment. Adjuvant treatment after surgery was administered to 14/26 patients (53.8%). Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival. However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054). CONCLUSIONS: The preoperative differential diagnosis of ESSs from other benign gynecologic diseases is often difficult. We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis.
Authors: Daniel Pink; Tanja Lindner; Alicia Mrozek; Albrecht Kretzschmar; Peter C Thuss-Patience; Bernd Dörken; Peter Reichardt Journal: Gynecol Oncol Date: 2005-12-20 Impact factor: 5.482
Authors: A Gadducci; E Sartori; F Landoni; P Zola; T Maggino; A Urgesi; A Lissoni; G Losa; A Fanucchi Journal: Gynecol Oncol Date: 1996-11 Impact factor: 5.482
Authors: Y C Lin; A P Kudelka; D Tresukosol; A Malpica; C H Carrasco; D D Lawrence; R E Collier; A Munoz; L Delclos; J J Kavanagh Journal: Gynecol Oncol Date: 1995-08 Impact factor: 5.482
Authors: Andrew J Li; Robert L Giuntoli; Richard Drake; Sharon Young Byun; Francisco Rojas; Denise Barbuto; Nancy Klipfel; Pamela Edmonds; David S Miller; Beth Y Karlan Journal: Obstet Gynecol Date: 2005-12 Impact factor: 7.661
Authors: F Amant; A De Knijf; B Van Calster; K Leunen; P Neven; P Berteloot; I Vergote; S Van Huffel; P Moerman Journal: Br J Cancer Date: 2007-09-25 Impact factor: 7.640